First Tracks Biotherapeutics, Inc. Ordinary Shares TRAX Business Segments
| Q1 '26 | ||
|---|---|---|
| Research And Development Expense Reversal Excluding Acquired In Process Cost by Business | ||
| ANB032 | -$31K-101% | |
| ANB033 | $9.3M+145% | |
| ANB101 | $1.48M+0.2% | |
| Preclinical And Other Unallocated Costs | $3.3M-16.2% | |
| Rosnilimab | $4.59M-69.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does First Tracks Biotherapeutics, Inc. Ordinary Shares break its business down?
- First Tracks Biotherapeutics, Inc. Ordinary Shares (TRAX) reports research and development expense reversal excluding acquired in process cost by business across 5 parts — ANB032, ANB033, ANB101, Preclinical And Other Unallocated Costs and Rosnilimab. Each is extracted from the segment footnotes and tracked over time.
- Where does First Tracks Biotherapeutics, Inc. Ordinary Shares's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in First Tracks Biotherapeutics, Inc. Ordinary Shares's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.